U.S. Optic Neuritis Market – Industry Trends and Forecast to 2029

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 무료 샘플 보고서 무료 샘플 보고서 구매하기 전에 문의 구매하기 전에 문의 지금 구매 지금 구매

U.S. Optic Neuritis Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Published Report
  • Sep 2022
  • Country Level
  • 350 Pages
  • 테이블 수: 8
  • 그림 수: 34

민첩한 공급망 컨설팅으로 관세 문제를 극복하세요

공급망 생태계 분석이 이제 DBMR 보고서의 일부가 되었습니다

Us Optic Neuritis Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Chart Image USD 4.15 Million USD 6.11 Million 2021 2029
Diagram 예측 기간
2022 –2029
Diagram 시장 규모(기준 연도)
USD 4.15 Million
Diagram 시장 규모(예측 연도)
USD 6.11 Million
Diagram 연평균 성장률
%
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

U.S. Optic Neuritis Market, By Treatment (Corticosteroids, IV Immunoglobulin, Supplements, and Others), Diagnosis (MRI Scan, Lumbar Puncture, Occular Coherence Tomography, Blood Test, and Others), Route of Administration (Parenteral, and Oral), End User (Hospitals, Clinics, Academics & Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others). Industry Trends and Forecast to 2029.

U.S. Optic Neuritis Market Analysis and Size

The growing prevalence of eye disorders in the region and the rise in the geriatric population has enhanced the demand of the market. The rising healthcare expenditure for better health services is also attributed to the growth of the market. The major market players are highly focused on product launches and approvals during this crucial period. In addition, the government and regulatory bodies are supporting market players by product approval due to the surging emergence.

U.S. Optic Neuritis Market

U.S. Optic Neuritis Market

The U.S. optic neuritis market is expected to reach USD 6.11 million by 2029 from USD 4.15 million in 2021, growing at a CAGR of 5.0% in the forecast period of 2022 to 2029.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2015)

Quantitative Units

Revenue in USD Million

Segments Covered

By Treatment (Corticosteroids, IV Immunoglobulin, Supplements, and Others), Diagnosis (MRI Scan, Lumbar Puncture, Ocular Coherence Tomography, Blood Test, and Others), Route of Administration (Parenteral, and Oral), End User (Hospitals, Clinics, Academics & Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others)

Countries Covered

U.S.

Market Players Covered

AbbVie Inc., Bausch & Lomb Incorporated, Boehringer Ingelheim International GmbH, Novartis AG, Merck & Co., Inc., Hikma Pharmaceuticals PLC, Fresenius Kabi USA, Teva Pharmaceuticals Industries Ltd., GSK plc, Pfizer, Akorn Operating Company LLC, AdvaCare Pharma, Bristol- Myers Squibb Company, Jubilant Cadista Pharmaceuticals Inc., Amneal Pharmaceuticals LLC., Viatris Inc., and Novitium Pharma, among others. The pipeline companies that are in this market are Accure Therapeutics, Noveome Biotherapeutics, Inc., Biogen, Mallinckrodt, and Acorda Therapeutics, Sanofi, among others.

Market Definition

Optic neuritis is characterized as a swelling or inflammation that occurs in the optic nerve. It is also commonly termed as optic papillitis and retro tubular neuritis. The optic nerves is a nerve fibres that has the capability of transmitting visual information from the eye to the brain. The inflammation usually leads to damage in the optic nerve and temporary vision loss in only one eye typically. Pediatric optic neuritis and adult optic neuritis and are two types which is based on the age group of patients diagnosed with optic neuritis. The common way to diagnose the optic neuritis is through a physical exam and medical history. The treatment becomes essential at an early stage due to the lifetime risk of losing human eye vision in this disorder. The most common symptoms associated with optic neuritis include pain with eye movement and dyschromatopsia or inability to see colors correctly. For instance, as per an article in the Journal of Neurology stated that the annual incidence of optic neuritis in the U.S. is found to be around 5/1,000,000, with an estimated prevalence of 115/1,000,000.

Optic Neuritis Market Dynamics

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail as below:

Drivers

  • Rising prevalence of eye disorders

With the increased prevalence and optic neuritis worldwide, there is an increase in the awareness about the disease. Therefore, rising patient awareness of optic neuritis is expected to act as a driver for the growth of the optic neuritis market.

  • Rise in traumatic injuries

Another significant factor influencing the growth rate of the optic neuritis market is the increasing prevalence of the disease in the region.

  • Increase in aging population

An increase in the aging population, rise in the multiple sclerosis patient pool, growing awareness, and affordable prices are the major factors propelling the market.

U.S. Optic Neuritis Market

Opportunities

  • Strategic initiatives of key players

The dramatic rise in the quality of research and increasing research opportunities is because of various strategic initiatives taken by the key market players in the optic neuritis market. They are taking initiatives such as product launches, collaborations, mergers, acquisitions, and many more over the years and are expected to lead and create more opportunities in the market.

Also, the rise in healthcare expenditure will provide structural integrity and future opportunities for the optic neuritis market in the forecast period of 2022-2029.

Restraints/Challenges

  • High cost associated with optic nerve disorders treatment

However, the high cost of therapies and side effects and complications of various drugs and therapies will impede the growth rate of the optic neuritis market. Additionally, stringent rules and regulations will further challenge the market in the forecast period mentioned above.

This optic neuritis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. For more info on the optic neuritis market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you to make an informed market decision to achieve market growth.

Recent Development

Sanofi is recently working on a single oral doses study of nerispirdine on visual function in patients with multiple sclerosis.

The U.S. Optic Neuritis Market Scope

The U.S. optic neuritis market is segmented into treatment, diagnosis, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Treatment

  • Corticosteroids
  • IV Immunoglobulin
  • Supplements
  • Others

On the basis of treatment, the U.S. optic neuritis market is segmented into corticosteroids, IV Immunoglobulin, Supplements, and Others.

Diagnosis

  • MRI Scan
  • Lumbar Puncture
  • Ocular Coherence Tomography
  • Blood Test
  • Others

On the basis of diagnosis, the U.S. optic neuritis market is segmented into MRI scans, lumbar puncture, ocular coherence tomography, blood test, and others.

Route of Administration

  • Parenteral
  • Oral

On the basis of route of administration, the U.S. optic neuritis market is segmented into parenteral, and oral.

End User

  • Hospitals
  • Clinics
  • Academic & Research Institutes
  • Others

On the basis of end-user, the U.S. optic neuritis market is segmented into hospitals, clinics, academic and research institutes, and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

U.S. Optic Neuritis Market

On the basis of distribution channel, the U.S. optic neuritis market is segmented into hospital pharmacy, retail pharmacy, and others.

Optic Neuritis Market Regional Analysis/Insights                 

The optic neuritis market is analyzed, and market size insights and trends are provided by country, treatment, diagnosis, route of administration, end user, and distribution channel, as referenced above.

The U.S. dominates the optic neuritis market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to implementing awareness programs regarding the diagnosis and treatments of optic neuritis, and research and development in the drugs for optic neuritis in the U.S. region further improves this market growth.

The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Optic Neuritis Market Share Analysis

The optic neuritis market competitive landscape provides details by the competitors. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the optic neuritis market.

Some of the major players operating in the optic neuritis market are AbbVie Inc., Bausch & Lomb Incorporated, Boehringer Ingelheim International GmbH, Novartis AG, Merck & Co., Inc., Hikma Pharmaceuticals PLC, Fresenius Kabi USA, Teva Pharmaceuticals Industries Ltd., GSK plc, Pfizer, Akorn Operating Company LLC, AdvaCare Pharma, Bristol- Myers Squibb Company, Jubilant Cadista Pharmaceuticals Inc., Amneal Pharmaceuticals LLC., Viatris Inc., and Novitium Pharma, among others. The pipeline companies that are in this market are Accure Therapeutics, Noveome Biotherapeutics, Inc., Biogen, Mallinckrodt, Acorda Therapeutics, and Sanofi, among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include the Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, U.S. vs. Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF U.S. OPTIC NEURITIS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TREATMENT LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL

4.2 PORTER'S FIVE FORCES MODEL

5 EPIDEMIOLOGY

6 INDUSTRY INSIGHTS

6.1 PATENT ANALYSIS

6.2 DRUG TREATMENT RATE BY MATURED MARKETS

6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

6.4 PATIENT FLOW DIAGRAM

6.5 KEY PRICING STRATEGIES

6.6 KEY PATIENT ENROLLMENT STRATEGIES

7 PIPELINE ANALYSIS

8 U.S. OPTIC NEURITIS MARKET: REGULATIONS

8.1 REGULATION IN THE U.S.:

9 MARKET OVERVIEW

9.1 DRIVERS

9.1.1 RISING PREVALENCE OF EYE DISORDERS

9.1.2 INCREASE IN AGING POPULATION

9.1.3 RISE IN TRAUMATIC INJURIES

9.2 RESTRAINTS

9.2.1 HIGH COST ASSOCIATED WITH OPTIC NERVE DISORDERS TREATMENT

9.2.2 RISKS ASSOCIATED WITH VARIOUS TREATMENTS METHODS

9.3 OPPORTUNITIES

9.3.1 RISE IN HEALTHCARE EXPENDITURE

9.3.2 STRATEGIC INITIATIVES OF KEY PLAYERS

9.4 CHALLENGES

9.4.1 NEGATIVE EFFECTS OF SYSTEMIC STEROIDS

9.4.2 LACK OF AWARENESS AMONG PEOPLE REGARDING DIFFERENT EYE TREATMENTS

10 U.S. OPTIC NEURITIS MARKET, BY TREATMENT

10.1 OVERVIEW

10.2 CORTICOSTEROIDS

10.2.1 METHYLPREDNISOLONE

10.2.2 PREDNISONE

10.2.3 OTHERS

10.3 IV IMMUNOGLOBULIN

10.4 SUPPLEMENTS

10.5 OTHERS

11 U.S. OPTIC NEURITIS MARKET, BY DIAGNOSIS

11.1 OVERVIEW

11.2 MRI SCAN

11.3 BLOOD TEST

11.4 OCULAR COHERENCE TOMOGRAPHY

11.5 LUMBAR PUNCTURE

11.6 OTHERS

12 U.S. OPTIC NEURITIS MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 PARENTERAL

12.3 ORAL

13 U.S. OPTIC NEURITIS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITALS

13.3 CLINICS

13.4 ACADEMIC AND RESEARCH INSTITUTES

13.5 OTHERS

14 U.S. OPTIC NEURITIS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 HOSPITAL PHARMACY

14.3 RETAIL PHARMACY

14.4 OTHERS

15 U.S. OPTIC NEURITIS MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: UNITED STATES

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 PFIZER INC.

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 PRODUCT PORTFOLIO

17.1.4 RECENT DEVELOPMENT

17.2 NOVARTIS AG

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 PRODUCT PORTFOLIO

17.2.4 RECENT DEVELOPMENT

17.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 PRODUCT PORTFOLIO

17.3.4 RECENT DEVELOPMENT

17.4 VIATRIS INC.

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 PRODUCT PORTFOLIO

17.4.4 RECENT DEVELOPMENT

17.5 BAUSCH & LOMB INCORPORATED

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 PRODUCT PORTFOLIO

17.5.4 RECENT DEVELOPMENTS

17.6 BRISTOL – MYERS SQUIBB COMPANY

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENT

17.7 FRESENIUS KABI USA

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENT

17.8 ABBVIE INC.

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 PRODUCT PORTFOLIO

17.8.4 RECENT DEVELOPMENT

17.9 ADVACAREPHARMA

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENT

17.1 AKORN OPERATING COMPANY LLC.

17.10.1 COMPANY SNAPSHOT

17.10.2 PRODUCT PORTFOLIO

17.10.3 RECENT DEVELOPMENT

17.11 AMNEAL PHARMACEUTICALS LLC

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE ANALYSIS

17.11.3 PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENT

17.12 GSK PLC

17.12.1 COMPANY SNAPSHOT

17.12.2 REVENUE ANALYSIS

17.12.3 PRODUCT PORTFOLIO

17.12.4 RECENT DEVELOPMENT

17.13 HIKMA PHARMACEUTICALS PLC

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

17.14 JUBILANT CADISTA

17.14.1 COMPANY SNAPSHOT

17.14.2 PRODUCT PORTFOLIO

17.14.3 RECENT DEVELOPMENT

17.15 MERCK & CO., INC.

17.15.1 COMPANY SNAPSHOT

17.15.2 REVENUE ANALYSIS

17.15.3 PRODUCT PORTFOLIO

17.15.4 RECENT DEVELOPMENTS

17.16 NOVITIUM PHARMA

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENT

17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD.

17.17.1 COMPANY SNAPSHOT

17.17.2 REVENUE ANALYSIS

17.17.3 PRODUCT PORTFOLIO

17.17.4 RECENT DEVELOPMENT

17.18 ACCURE THEREPEUTICS

17.18.1 COMPANY SNAPSHOT

17.18.2 PRODUCT PORTFOLIO

17.18.3 RECENT DEVELOPMENT

17.19 ACORDA THERAPEUTICS INC.

17.19.1 COMPANY SNAPSHOT

17.19.2 REVENUE ANALYSIS

17.19.3 PRODUCT PORTFOLIO

17.19.4 RECENT DEVELOPMENT

17.2 BIOGEN INC.

17.20.1 COMPANY SNAPSHOT

17.20.2 REVENUE ANALYSIS

17.20.3 PRODUCT PORTFOLIO

17.20.4 RECENT DEVELOPMENT

17.21 MALLINCKRDOT PHARMACEUTICALS

17.21.1 COMPANY SNAPSHOT

17.21.2 REVENUE ANALYSIS

17.21.3 PRODUCT PORTFOLIO

17.21.4 RECENT DEVELOPMENT

17.22 NOVEOME BIOTHERAPEUTICS, INC.

17.22.1 COMPANY SNAPSHOT

17.22.2 PRODUCT PORTFOLIO

17.22.3 RECENT DEVELOPMENT

17.23 SANOFI

17.23.1 COMPANY SNAPSHOT

17.23.2 REVENUE ANALYSIS

17.23.3 PRODUCT PORTFOLIO

17.23.4 RECENT DEVELOPMENTS

18 QUESTIONNAIRE

19 RELATED REPORTS

표 목록

TABLE 1 U.S. OPTIC NEURITIS MARKET, PIPELINE ANALYSIS

TABLE 2 U.S. OPTIC NEURITIS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 3 U.S. OPTIC NEURITIS MARKET, BY TREATMENT, 2020-2029 (VOLUME IN MILLION)

TABLE 4 U.S. CORTICOSTEROIDS IN OPTIC NEURITIS MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 5 U.S. OPTIC NEURITIS MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 6 U.S. OPTIC NEURITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 7 U.S. OPTIC NEURITIS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 8 U.S. OPTIC NEURITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

그림 목록

FIGURE 1 U.S. OPTIC NEURITIS MARKET: SEGMENTATION

FIGURE 2 U.S. OPTIC NEURITIS MARKET: DATA TRIANGULATION

FIGURE 3 U.S. OPTIC NEURITIS MARKET: DROC ANALYSIS

FIGURE 4 U.S. OPTIC NEURITIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 U.S. OPTIC NEURITIS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 U.S. OPTIC NEURITIS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 U.S. OPTIC NEURITIS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 U.S. OPTIC NEURITIS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 U.S. OPTIC NEURITIS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 U.S. OPTIC NEURITIS MARKET: SEGMENTATION

FIGURE 11 THE INCREASING PREVALENCE OF EYE DISORDERS AND RISE IN THE GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE U.S. OPTIC NEURITIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 CORTICOSTEROIDS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. OPTIC NEURITIS MARKET IN 2022 AND 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE U.S. OPTIC NEURITIS MARKET

FIGURE 14 U.S. OPTIC NEURITIS MARKET: BY TREATMENT, 2021

FIGURE 15 U.S. OPTIC NEURITIS MARKET: BY TREATMENT, 2022-2029 (USD MILLION)

FIGURE 16 U.S. OPTIC NEURITIS MARKET: BY TREATMENT, CAGR (2022-2029)

FIGURE 17 U.S. OPTIC NEURITIS MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 18 U.S. OPTIC NEURITIS MARKET: BY DIAGNOSIS, 2021

FIGURE 19 U.S. OPTIC NEURITIS MARKET: BY DIAGNOSIS, 2022-2029 (USD MILLION)

FIGURE 20 U.S. OPTIC NEURITIS MARKET: BY DIAGNOSIS, CAGR (2022-2029)

FIGURE 21 U.S. OPTIC NEURITIS MARKET: BY DIAGNOSIS, LIFELINE CURVE

FIGURE 22 U.S. OPTIC NEURITIS MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 23 U.S. OPTIC NEURITIS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 24 U.S. OPTIC NEURITIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 25 U.S. OPTIC NEURITIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 26 U.S. OPTIC NEURITIS MARKET: BY END USER, 2021

FIGURE 27 U.S. OPTIC NEURITIS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 28 U.S. OPTIC NEURITIS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 U.S. OPTIC NEURITIS MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 U.S. OPTIC NEURITIS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 31 U.S. OPTIC NEURITIS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 32 U.S. OPTIC NEURITIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 33 U.S. OPTIC NEURITIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 34 U.S. OPTIC NEURITIS MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

시장은 U.S. Optic Neuritis Market, By Treatment (Corticosteroids, IV Immunoglobulin, Supplements, and Others), Diagnosis (MRI Scan, Lumbar Puncture, Occular Coherence Tomography, Blood Test, and Others), Route of Administration (Parenteral, and Oral), End User (Hospitals, Clinics, Academics & Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others). Industry Trends and Forecast to 2029. 기준으로 세분화됩니다.
U.S. Optic Neuritis Market의 시장 규모는 2021년에 4.15 USD Million USD로 평가되었습니다.
U.S. Optic Neuritis Market는 2022년부터 2029년까지 연평균 성장률(CAGR) 5%로 성장할 것으로 예상됩니다.
이 시장 보고서는 U.S.의 데이터를 포함합니다.
Testimonial